<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
    /* Dark mode support */
    @media (prefers-color-scheme: dark) {
      :root {
        --border: #374151;
        --muted: #9ca3af;
        --bg: #111827;
        --card: #1f2937;
        --soft: #374151;
        --accent: #60a5fa;
      }
      body { color: #f3f4f6; }
      h1, h2, h3 { color: #f9fafb; }
      table.grid th { background: #374151; color: #f3f4f6; }
      .refs-title { color: #f9fafb; }
      .ref-cat-header { background: linear-gradient(135deg, #374151 0%, #4b5563 100%); color: #f3f4f6; }
      .ref-entry { background: #374151; }
      .ref-details { color: #d1d5db; }
      .mermaid-chart { background: linear-gradient(135deg, #1f2937 0%, #374151 100%); }
      .stats-card { background: linear-gradient(135deg, #1e3a5f 0%, #1e293b 100%) !important; border-color: #0ea5e9 !important; }
      .stats-card h2 { color: #7dd3fc !important; }
    }
    /* Print button */
    .print-btn {
      position: fixed; top: 20px; right: 20px; z-index: 1000;
      padding: 10px 18px; cursor: pointer;
      background: linear-gradient(135deg, #2563eb 0%, #1d4ed8 100%);
      color: white; border: none; border-radius: 8px;
      font-size: 14px; font-weight: 600;
      box-shadow: 0 2px 8px rgba(37, 99, 235, 0.3);
      transition: all 0.2s ease;
    }
    .print-btn:hover { background: linear-gradient(135deg, #1d4ed8 0%, #1e40af 100%); transform: translateY(-1px); box-shadow: 0 4px 12px rgba(37, 99, 235, 0.4); }
    .print-btn:active { transform: translateY(0); }
    /* Print-friendly styles */
    @media print {
      body { margin: 0; background: white; }
      .card, details { border: 1px solid #ccc; page-break-inside: avoid; }
      details[open] > summary ~ * { display: block; }
      .mermaid-chart { page-break-inside: avoid; }
      .stats-card { background: #f0f9ff !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
      .no-print { display: none !important; }
    }
    /* Responsive layout */
    @media (max-width: 768px) {
      body { margin: 12px; }
      .cols { grid-template-columns: 1fr; }
      table.grid { font-size: 11px; }
      table.grid th, table.grid td { padding: 4px; }
    }
  </style>
</head>
<body>
  <button onclick="window.print()" class="print-btn no-print">ğŸ–¨ï¸ Print Report</button>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>ğŸ¯ Mode:</strong> <code style='background: #e0f2fe; padding: 2px 8px; border-radius: 4px; font-weight: 600;'>chair_sa_kep</code>
</div>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 37.2 seconds (37.2ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 26,328</li>
<li>Output: 1,546</li>
<li>Total: 27,874</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>gpt-5.1 (Azure)</strong>: 
6 calls, 
27,874 tokens 
(26,328 in / 1,546 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-22_18-33-38</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Highâ€‘grade serous ovarian carcinoma, HRDâ€‘positive, BRCAâ€‘wild type, postâ€‘primary surgery and 1L platinum, currently NED on PARP maintenance.[@2022-10-25|MR][@2022-09-29|CT][@OH2201222|2022-01-24 | Genomics] Hematologic and organ function are now acceptable; prior severe thrombocytopenia on PARP has resolved.[@20230109|5600622 | LAB][@2022-04-18|Blood routine | LAB] Key uncertainties: exact current PARP dose/schedule, cumulative duration of maintenance, and formal FIGO stage.

Core Treatment Strategy:
- Continue PARP maintenance with individualized dose, given HRD+ status and no radiologic recurrence or biomarker progression.[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8][@2022-10-25|MR]
- Intensify CBC monitoring (e.g., monthly initially) and adjust/interrupt PARP promptly for recurrent thrombocytopenia or cytopenias.[@pubmed | 40687421][@20230109|5600622 | LAB]
- Maintain surveillance with 3â€“6â€‘monthly CA125/HE4 and crossâ€‘sectional imaging; document formal stage and prior response status.[@20230109|9701878 | LAB][@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]
- Clarify germline counseling history; if not done, refer for genetic counseling despite negative panel, to address familial risk.[@OH2201222|2022-01-24 | Genomics]

Change Triggers:
- If platelets fall &lt;100Ã—10â¹/L or symptomatic bleeding, stepwise PARP dose reduction or temporary discontinuation, consider alternative maintenance.
- If imaging/markers show recurrence, reâ€‘stage, biopsy if feasible, and pivot to platinumâ€‘based systemic therapy Â± surgery.[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
- If cumulative PARP duration reaches locally recommended limit (e.g., 2â€“3 years), reassess riskâ€“benefit and consider elective discontinuation.[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 8</div>
<div class='ref-detail-line'>Content: MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-</div>
<div class='ref-detail-line'>ity...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: nccn_ovariancancer_v3_2025__v00000000, Page 12</div>
<div class='ref-detail-line'>Content: Version 3.2025, 07/16/25 Â© 2025 National Comprehensive...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: nccn_ovariancancer_v3_2025__v00000000, Page 15</div>
<div class='ref-detail-line'>Content: based chemotherapy,n</div>
<div class='ref-detail-line'>preferred for first</div>
<div class='ref-detail-line'>recurrence...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
<div class='ref-entry'>
<div class='ref-tag'>[@pubmed | 40687421]</div>
<div class='ref-details'>
<div class='ref-detail-line'>PMID: 40687421 | Front Oncol | 2025-01-01</div>
<div class='ref-detail-line'>Title: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.</div>
<div class='ref-detail-line'>DOI: 10.3389/fonc.2025.1542646</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2201222|2022-01-24 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2201222|2022-01-24</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|5600622 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|5600622 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN) PLTåˆ†å¸ƒå®½åº¦ 10 % (PDW) å—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|9701878 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|9701878 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125) äººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-10-25|MR]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Report ID: 2022-10-25 | Date: MR</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-09-29|CT]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Report ID: 2022-09-29 | Date: CT</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-04-18|Blood routine | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 2022-04-18|Blood routine</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢ç™Œï¼šæµè°ƒå¦è®¤ä¸­é«˜é£é™©åœ°åŒºæ—…å±…å²ï¼Œå¦è®¤ä½“æ¸©å¼‚å¸¸ç­‰æ–°å† è‚ºç‚ç—‡çŠ¶ã€‚2021.08.26åœ¨å…¨éº»ä¸‹è¡Œæ‰©å¤§æ€§å…¨å­å®«åˆ‡é™¤æœ¯+åŒé™„ä»¶åˆ‡é™¤æœ¯+ç›†è…”è‚¿å—åˆ‡é™¤æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+ä¹™çŠ¶ç»“è‚ é€ å£æœ¯+å¤§ç½‘è†œåˆ‡é™¤æœ¯+ç›†è…”æ·‹å·´ç»“æ¸…æ‰«æœ¯+é˜‘å°¾åˆ‡é™¤æœ¯+è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“æ¸…æ‰«æœ¯ã€‚æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ .
2021.09.06ã€09.07äºˆé¡ºé“‚50mgè…¹è…”åŒ–ç–—ã€2021.10.18èµ·è¡ŒTPåŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡åŒ–ç–—2022.3.22æˆ‘é™¢åŸºå› æ£€æµ‹ç»“æœï¼šHRD(+)æœç”¨å°¼æ‹‰å¸•åˆ©1å‘¨ï¼Œè¯‰ååº”å¤§ï¼Œè‡ª2022.4.26å¼€å§‹åœè¯ã€‚2022.4.18è¡€å¸¸è§„ï¼šPLT:33ä»Šæ—¥è¡€å¸¸è§„ï¼šPLT:342022.5.23èµ·æ¢å¤å°¼æ‹‰å¸•åˆ©1#qdã€‚
ç›®å‰ååº”å¯ã€‚2022.6.24è‡³ä¸­å±±åŒ»é™¢è¡Œè…¹å£ç–ä¿®è¡¥æœ¯ã€‚å› æ‰‹æœ¯å°¼æ‹‰å¸•åˆ©åœè¯3å‘¨ã€‚ç›®å‰ç»§ç»­å£æœå°¼æ‹‰å¸•åˆ©ä¸­ã€‚è¯‰æœ€è¿‘è…¹ç—›å‡ æ¬¡ï¼Œè…¹èƒ€æ˜æ˜¾ã€‚CTï¼ˆ2022.09.27ï¼‰ï¼šå³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
CTï¼ˆ2022.10.08ï¼‰ï¼šè‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚å·¦è‚¾å›Šè‚¿åŒå‰ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
MRï¼ˆ2022.10.25ï¼‰ï¼šåµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚æœ€è¿‘å¤æŸ¥æŠ¥å‘Šå¥½ã€‚2022.12.30ä¸­å±±åŒ»é™¢ï¼šåˆ‡å£ç–ï¼Œè‚å³å¶ä½å¯†åº¦ç¶ã€‚è¡€å¸¸è§„ã€è‚è‚¾åŠŸèƒ½ä¸€èˆ¬å¯; ECOG=1</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;TP&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;Unknown&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;Adenocarcinoma&quot;,&quot;High-grade serous carcinoma&quot;],&quot;histology&quot;:&quot;High-grade serous carcinoma&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;ECOG&quot;:&quot;1&quot;,&quot;GENOMICS&quot;:{&quot;HRD_STATUS&quot;:{&quot;method&quot;:&quot;Unknown&quot;,&quot;result&quot;:&quot;Positive&quot;,&quot;score&quot;:&quot;Unknown&quot;},&quot;alterations&quot;:[],&quot;testing_date&quot;:&quot;Unknown&quot;,&quot;testing_performed&quot;:&quot;Yes&quot;,&quot;testing_platform&quot;:&quot;Unknown&quot;},&quot;HRD&quot;:&quot;Positive&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;1&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Switched to TP chemotherapy&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;2021-09-07&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;41&quot;,&quot;regimen&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-09-06&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;6&quot;,&quot;cycles_planned&quot;:&quot;6&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Completed 6 cycles&quot;,&quot;reason&quot;:&quot;Completed&quot;},&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;TP&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-10-18&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;Unknown&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;Unknown&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;Maintenance&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2022-04-Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Yes&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;å°¼æ‹‰å¸•åˆ©&quot;],&quot;start_date&quot;:&quot;2022-04-Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;evidence&quot;:&quot;TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2021-10-18&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;No&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;SCENE&quot;:&quot;Maintenance_surveillance_followup&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-09&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-03-22&quot;},&quot;CLINICAL_TRIALS&quot;:[],&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;Other&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary debulking surgery for ovarian cancer&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Completed TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Thrombocytopenia (PLT 33) on blood routine&quot;,&quot;type&quot;:&quot;Other&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[&quot;HRD&quot;]},&quot;monitoring_points&quot;:[{&quot;drug_or_class&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;monitoring&quot;:[&quot;Monitor platelet count due to prior thrombocytopenia&quot;]}],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;TP&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;High-grade serous carcinoma&quot;,&quot;Myometrial leiomyomas&quot;,&quot;Chronic cervicitis&quot;],&quot;date&quot;:&quot;2021-08-26&quot;,&quot;diagnosis&quot;:&quot;Adenocarcinoma consistent with high-grade serous carcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Left ovary&quot;,&quot;Right ovary&quot;,&quot;Left fallopian tube&quot;,&quot;Right fallopian tube&quot;,&quot;Uterine myometrium&quot;,&quot;Pelvic and abdominal peritoneum&quot;,&quot;Partial rectosigmoid colon from serosa to superficial muscle&quot;,&quot;Omentum&quot;,&quot;Left paracolic gutter peritoneum&quot;,&quot;Small bowel mesentery&quot;,&quot;Sigmoid mesentery&quot;,&quot;Appendiceal serosa&quot;,&quot;Pelvic lymph nodes&quot;,&quot;Para-aortic and mesenteric lymph nodes (some positive)&quot;],&quot;laterality&quot;:&quot;Bilateral ovarian involvement&quot;,&quot;molecular&quot;:[{&quot;result&quot;:&quot;Positive&quot;,&quot;test&quot;:&quot;HRD&quot;}],&quot;raw_text&quot;:&quot;æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ã€‚&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes&quot;,&quot;tumor_size&quot;:&quot;Left ovary 3.5Ã—2Ã—1.5cm; right ovary 6Ã—5.5Ã—4.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;FIGO stage not provided&quot;,&quot;IHC panel details not provided&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Lung&quot;,&quot;Pleura&quot;,&quot;Chest&quot;],&quot;date&quot;:&quot;2022-09-27&quot;,&quot;findings&quot;:[&quot;Right upper lung arteriovenous fistula similar to prior&quot;,&quot;Right upper lung apical segment small nodule similar to prior&quot;,&quot;Left upper lung scattered tiny nodules&quot;,&quot;Small bilateral pleural effusions decreased compared with prior&quot;,&quot;Scattered chronic inflammatory and fibrotic changes in lungs&quot;,&quot;Atelectasis improved&quot;,&quot;Nodule at right cardiophrenic angle less apparent&quot;],&quot;impression&quot;:&quot;Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Improved&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;,&quot;Kidney&quot;,&quot;Spine&quot;],&quot;date&quot;:&quot;2022-10-08&quot;,&quot;findings&quot;:[&quot;Hemangioma in liver right lobe segment VII similar to prior&quot;,&quot;Left renal cyst similar to prior&quot;,&quot;Localized uneven sclerotic change in lumbar vertebrae similar to prior&quot;],&quot;impression&quot;:&quot;Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Postoperative changes after ovarian cancer surgery&quot;,&quot;No abnormal soft tissue mass in pelvis&quot;],&quot;impression&quot;:&quot;No pelvic recurrence; follow-up recommended&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;TOXICITIES&quot;:[{&quot;attribution&quot;:&quot;Probable&quot;,&quot;dose_modification&quot;:&quot;Yes&quot;,&quot;onset_date&quot;:&quot;2022-04-18&quot;,&quot;outcome&quot;:&quot;Resolved&quot;,&quot;related_line&quot;:&quot;1L&quot;,&quot;related_regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;severity&quot;:&quot;Severe&quot;,&quot;toxicity&quot;:&quot;Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)&quot;}]}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: None
- name: None
- Reason: Disease is not clearly recurrent/advanced for 2L+ and required biomarkers (e.g., HER2, TF, HPV16, HER2 activating mutation) are not documented.
- Missing eligibility confirmations (0-2 items):
  - HER2 / TF / HPV16 / HER2 activating mutation status
  - Clear documentation of recurrent, unresectable, or metastatic disease after standard treatment failure</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>ğŸ“‹ MDT Discussion Summary (Assistant)</summary>
    <pre>(Chair-SA(K+EP): Single agent mode - no MDT discussion)</pre>
    <div class="hint">Structured summary of Key Knowledge, Controversies, Missing Info, and Working Plan.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <div class='warn'>No interaction log captured.</div>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;(Single agent mode with Evidence Pack)&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-09</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20230109|5600622&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 10 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 1.00 % (BASO)\næ·‹å·´ç»†èƒ% 28.8 % (LYM)\nå•æ ¸ç»†èƒ% 7.5 % (MID)\nå—œé…¸æ€§ç»†èƒæ•° 0.04 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.70 % (EOS)\nå¹³å‡PLTå®¹ç§¯ 9.4 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 2.18 nan (NL)\nçº¢ç»†èƒè®¡æ•° 3.96 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 145 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 11.8 % (RDWCV)\nçº¢ç»†èƒæ¯”ç§¯ 37.7 % (HCT)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 31.6 pg (MCH)\næ·‹å·´ç»†èƒæ•° 1.7 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 3.7 *10^9/L (GRAN#)\nç™½ç»†èƒè®¡æ•° 6.0 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 125 g/l (HGB)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 95.2 fl (MCV)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— ACCEPT nan (VFLAG)\nå•æ ¸ç»†èƒæ•° 0.5 *10^9/L (MID#)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 332.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.14 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 41 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|8300382&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT)\nå°¿ç´  4.65 mmol/l (UREA)\nä¹³é…¸è„±æ°¢é…¶ 267 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.1 U/l (ALT)\nè‚Œé… 68 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.87 nan (A/G)\nç¢±æ€§ç£·é…¸é…¶ 96.3 U/L (ALP)\nå‰ç™½è›‹ç™½ 234 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  5.0 umol/L (IBIL)\næ€»èƒ†çº¢ç´  9.6 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 2.4 U/L (GLDH)\nç›´æ¥èƒ†çº¢ç´  4.6 umol/l (DBIL)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.68 mmol/L (NEFA)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.5 U/L (AST)\nå°¿é…¸ 242 umol/l (UA)\nç™½è›‹ç™½ 45.7 g/l (ALB)\næ€»è›‹ç™½ 70.1 g/l (TP)\nè°·è‰åŒå·¥é…¶ 8.3 U/L (ASTM)\nçƒè›‹ç™½ 24.4 g/l (GELO)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|9701878&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125)\näººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 18.17 %(ç»ç»å‰) (ROMA)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 10.06 %(ç»ç»å) (ROMA.)&quot;
      }
    ]
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ]
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>HRDâ€‘positive, BRCA1/2â€‘negative highâ€‘grade serous ovarian carcinoma, postâ€“primary debulking and firstâ€‘line platinum chemotherapy (platinumâ€‘sensitive), with prior extensive peritoneal and nodal metastases; history of severe niraparibâ€‘induced thrombocytopenia but organ function otherwise acceptable; histology: High-grade serous carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6817 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCCâ€¦
[2] score=0.6687 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 10] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]
    platinum-based ChT followed by niraparib or rucaparib if in CR/PR/NED [I, B]. Consensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36 voters) Recommendation 13.9: When used as maintenance in patients in CR/PR/NED to platinum-based ChT, olaparib (alone or in combination with bevacizumab) and rucaparibâ€¦
[3] score=0.6681 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 8] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]
    MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil- ity of molecular Targets (ESCAT) score: I-A], niraparib for 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or olaparibebevacizumab for 2 years [ESMO- MCBS v1.1 score: 3; ESCAT score: I-A]. o For BRCA1/2-wt/HRD-positive: niraparib for 3 yeaâ€¦
[4] score=0.6616 nccn_ovariancancer_v3_2025__v00000000 [PAGE 12] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]
    Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Guiâ€¦
[5] score=0.6609 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 11] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
    cytoreduction o Residual ChT toxicity o The patientâ€™s general condition and preferences  Patients with ï¬rst relapse of ovarian cancer after &gt;6 months of last platinum administration should be evalu- ated by a gynaecological oncology centre experienced in surgery for ovarian cancer to identify potenâ€¦

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7430 PMID 35359396 [@pubmed | 35359396]
    Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of
    Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niâ€¦
[2] score=0.7162 PMID 40687421 [@pubmed | 40687421]
    Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.
    Ovarian cancer (OC) is a common gynecological malignancy, and poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy has significantly prolonged the survival of newly diagnosed or platinum-sensitive recurrent ovarian cancer patients, which has become a new treatment paradigm for ovarian â€¦
[3] score=0.7056 PMID 40777128 [@pubmed | 40777128]
    Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.
    [This corrects the article DOI: 10.3389/fonc.2025.1542646.].
[4] score=0.6824 PMID 33376347 [@pubmed | 33376347]
    Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic
    Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation sâ€¦
[5] score=0.6812 PMID 31205507 [@pubmed | 31205507]
    Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patienâ€¦</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6817038059234619,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\nâ€¢ Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n â—ŠIf not previously used (category 1)\n â—ŠIf disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6687229871749878,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;platinum-based ChT followed by niraparib or rucaparib if\nin CR/PR/NED [I, B].\nConsensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36\nvoters)\nRecommendation 13.9: When used as maintenance in\npatients in CR/PR/NED to platinum-based ChT, olaparib\n(alone or in combination with bevacizumab) and rucaparib\nare recommended for 2 years, and niraparib is recom-\nmended for 3 years [I, A].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\n14. How should older/frail patients with tubo-ovarian\ncarcinoma be investigated and treated?\nOlder patients are under-represented in clinical trials due\nto their poor performance status (PS) and comorbidities,88\nand their outcomes are poorer.89 Geriatric assessment\ngathers information on functional, mental and nutritional\nstatus, emotional conditions and social support.90 Vulner-\nability scores have been validated in clinical trials.90,91\nSurgery, frequently carried out in an emergency context\nand in unspecialised centres, is often incomplete, with\nhigher\npost-operative\ncomplications.92\nChT\nmay\nbe\nunderutilised.93,94\nRecommendation 14.1: Patients should not be excluded\nfrom diagnostic procedures, clinical trials and speciï¬c&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6680895090103149,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-\nity of molecular Targets (ESCAT) score: I-A], niraparib\nfor 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score:\nI-A] or olaparibebevacizumab for 2 years [ESMO-\nMCBS v1.1 score: 3; ESCAT score: I-A].\no For BRCA1/2-wt/HRD-positive: niraparib for 3 years\n[ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or\nolaparibebevacizumab for 2 years [ESMO-MCBS v1.1\nscore: 3; ESCAT score: I-A).\n\u0004 Maintenance treatment with either bevacizumab [I, A] or\nniraparib for 3 years [I, B; ESMO-MCBS v1.1 score: 3] can\nbe recommended for HRD-negative tumours, with the\nlatter\nfollowing\ncomplete\nor\npartial\nresponse\nto\nplatinumepaclitaxel ï¬rst-line ChT. The choice of treat-\nment should be based on disease and clinical character-\nistics of the patient.\n\u0004 Maintenance with anti-estrogen therapy after ï¬rst-line\nplatinum-based ChT can be considered in LGSC [IV, B].\nMANAGEMENT OF RECURRENT EOC\nPatient assessment\nUp to 70% of patients with stage III-IV high-grade ovarian\ncancer will relapse within 3 years. Relapse rates for early-\nstage ovarian cancer are much lower.\nSeveral factors need to be assessed when selecting a&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6615776419639587,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 12,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nCRx/PR\nOV-5\nSTAGE II, III, IVw\nPOST PRIMARY TREATMENT\nHR\ndeficient\nHomologous\nrecombination (HR)\nproficient or status\nunknown\nOlaparib (category 1)\nor\nNiraparib (category 1)\nor\nRucaparib\nor\nObserve for select stage II disease with CR\nObserve (if CR)\nor\nNiraparib (HR deficient)\nor\nRucaparib\nor\nOlaparib (HR deficient) (category 2B)\nor\nTherapy for Persistent Disease or Recurrence (OV-7)\nMonitoring/\nFollow-up (OV-6)\nMonitoring/\nFollow-Up (OV-6)\nMAINTENANCE THERAPYh,n,y\nBevacizumab\nused as part\nof primary\ntherapy\nNo\nbevacizumab\nused during\nprimary\ntherapy\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nBevacizumab + olaparib (category 1)\nor&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6609175205230713,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;cytoreduction\no Residual ChT toxicity\no The patientâ€™s general condition and preferences\n\u0004 Patients with ï¬rst relapse of ovarian cancer after &gt;6\nmonths of last platinum administration should be evalu-\nated by a gynaecological oncology centre experienced in\nsurgery for ovarian cancer to identify potential candi-\ndates for surgical cytoreduction [I, A].\n\u0004 Patients who have previously responded to platinum\nwithout early symptomatic relapse should be treated\nwith either a platinum-based doublet (PLD, gemcitabine\nor paclitaxel) with bevacizumab [I, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3]\nor a platinum-based doublet followed by maintenance\nwith PARPi therapy if a response is achieved and the\npatient has not been previously exposed to PARPis\n[I, A; olaparib for BRCA1/2-mutated: ESMO-MCBS v1.1\nscore: 2; niraparib regardless of BRCA1/2-mut status:\nESMO-MCBS v1.1 score: 3; rucaparib regardless of\nBRCA1/2-mut status: ESMO-MCBS v1.1 score: 3].\n\u0004 For patients requiring rapid response, the combination\nof a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.7429660488046521,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35359396&quot;,
    &quot;title&quot;: &quot;Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of&quot;,
    &quot;abstract&quot;: &quot;Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2022.853211&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7429660488046521
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.7161524747944363,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;40687421&quot;,
    &quot;title&quot;: &quot;Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.&quot;,
    &quot;abstract&quot;: &quot;Ovarian cancer (OC) is a common gynecological malignancy, and poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy has significantly prolonged the survival of newly diagnosed or platinum-sensitive recurrent ovarian cancer patients, which has become a new treatment paradigm for ovarian cancer. Niraparib is a widely used PARP inhibitor in the clinical setting, and its adverse effects are also a major concern. The common adverse reactions of Niraparib mainly include various hematological adverse reactions (such as thrombocytopenia and anemia), gastrointestinal adverse reactions (such as nausea and vomiting), and fatigue. In previous related reports, thrombocytopenia has been mentioned multiple times, a relatively common adverse reaction of Niraparib. However, there have been no reports of irreversible and persistent thrombocytopenia. This case report describes a 59-year-old woman who developed persistent thrombocytopenia 11 months after adjuvant chemotherapy for stage IIIC high-grade serous ovarian cancer. Despite various treatment measures, the patient&#x27;s platelet count continues to fluctuate and remains low. This is a severe thrombocytopenia that may rare adverse reaction caused by Niraparib. This article adds important information to the scientific literature on potential serious adverse reactions in long-term treatment with Niraparib. It emphasizes the necessity of closely monitoring platelet counts during Niraparib treatment.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2025-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2025.1542646&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7161524747944363
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.7055733346889699,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;40777128&quot;,
    &quot;title&quot;: &quot;Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.&quot;,
    &quot;abstract&quot;: &quot;[This corrects the article DOI: 10.3389/fonc.2025.1542646.].&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2025-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2025.1661708&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7055733346889699
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6824086335254597,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33376347&quot;,
    &quot;title&quot;: &quot;Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic&quot;,
    &quot;abstract&quot;: &quot;Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation status seems to be associated with the development of brain metastases from ovarian cancer and these patients may benefit from treatment with PARP (poly ADP ribose polymerase) inhibitors. Here is a case where a Chinese female patient diagnosed with high-grade serous ovarian cancer with brain metastases was detected to have known germline ATM mutation and somatic BRCA2 mutation. The patient underwent whole brain radiotherapy and systemic chemotherapy, commenced niraparib as maintenance treatment and then presented considerable clinical and radiological response.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2020-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S281302&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.6824086335254597
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6811652700024877,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;31205507&quot;,
    &quot;title&quot;: &quot;Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.&quot;,
    &quot;abstract&quot;: &quot;Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patients with a BRCAm derive the greatest benefit from PARP inhibitors. However, clinical studies have also shown that PARP inhibitors provide benefit to women with ovarian cancer who do not have a BRCAm. The recent updated approvals of olaparib, niraparib and rucaparib by the US Food and Drug Administration and the European Medicines Agency for the treatment of all platinum-sensitive relapsed (PSR) ovarian-cancer populations, regardless of their BRCAm status, support this. Long-term tolerability and efficacy of olaparib have been demonstrated in patients both with and without a BRCAm, with 13% of patients receiving maintenance olaparib for at least 5 years in one study, which is unprecedented in the relapsed ovarian-cancer setting (versus 1% on placebo). Further studies should be performed to elucidate which non-BRCAm patients are deriving benefit and what molecular processes are enabling this, so that patients continue to receive optimal treatment for their disease. Here, we review clinical and molecular markers of HRD, the long-term clinical safety and efficacy of PARP inhibitors in ovarian cancer, with a focus on olaparib and the current approved indications for PARP inhibitors, as well as guidance on treatment decisions for patients with PSR ovarian cancer.&quot;,
    &quot;journal&quot;: &quot;Ther Adv Med Oncol&quot;,
    &quot;pub_date&quot;: &quot;2019-01-01&quot;,
    &quot;doi&quot;: &quot;10.1177/1758835919849753&quot;,
    &quot;impact_factor&quot;: 4.2,
    &quot;similarity&quot;: 0.6811652700024877
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>- Consider platinum-based chemotherapy as preferred treatment at first recurrence, with possible secondary cytoreductive surgery and/or best supportive care depending on overall goals and fitness. [1] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]

- For patients in CR/PR/NED after platinum-based chemotherapy, maintenance with niraparib or rucaparib is recommended; olaparib alone or with bevacizumab is also an option depending on prior treatment and biomarker status. [2] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]

- In newly diagnosed or recurrent settings, PARP inhibitor maintenance options include olaparib, niraparib, or olaparibâ€“bevacizumab, with choice guided by BRCA/HRD status and planned duration (typically 2â€“3 years). [3] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]

- NCCN recommends, in the absence of contraindications, considering platinum-based regimens and maintenance strategies (including PARP inhibitors and/or bevacizumab) for appropriate stages and recurrence patterns, with most recommendations being category 2A. [4] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]

- At first relapse occurring &gt;6 months after last platinum, referral to an experienced gynecologic oncology center for evaluation of secondary cytoreductive surgery is advised, taking into account residual toxicities and performance status. [5] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]

- Niraparib, while effective as maintenance in platinum-responsive ovarian cancer (especially BRCA-mutated), carries a risk of thromboembolic events such as pulmonary embolism, necessitating vigilance for symptoms and risk-factor assessment during therapy. [6] [@pubmed | 35359396]

- PARP inhibitor maintenance, including niraparib, has become a standard paradigm in newly diagnosed and platinum-sensitive recurrent ovarian cancer but may cause severe thrombocytopenia in some patients, requiring close hematologic monitoring, dose modification, or discontinuation. [7] [@pubmed | 40687421]

- Case experience indicates niraparib can be used in patients with specific DNA damage response gene alterations (e.g., ATM) and CNS involvement, supporting consideration of PARP inhibition in selected molecularly defined and advanced presentations, with individualized assessment. [8] [@pubmed | 40777128]

- Brain metastases from epithelial ovarian cancer are rare but can be managed with multimodal approaches (surgery, radiotherapy, systemic therapy), and PARP inhibitors may provide benefit in patients with BRCA or other HRD-related mutations; overall prognosis remains guarded. [9] [@pubmed | 33376347]

- Clinical trial data support olaparib maintenance in platinum-sensitive relapsed ovarian cancer, particularly in BRCA-mutated or HRD-positive disease, improving progression-free outcomes and reinforcing the role of PARP inhibition after response to platinum-based chemotherapy. [10] [@pubmed | 31205507]</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:01.462498&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;mode&quot;: &quot;chair_sa_kep&quot;,
      &quot;visit_time&quot;: &quot;2023-01-09 09:23:13.113000&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:01.462989&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;fa2f34f1e565&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:01.986586&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 152,
      &quot;img_n&quot;: 24,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:06.383946&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: 3,
      &quot;imaging&quot;: 3,
      &quot;pathology&quot;: 0,
      &quot;mutation&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:06.386035&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=Ovarian cancer; histology=High-grade serous carcinoma; components=Adenocarcinoma;High-grade serous carcinoma\nPATHOLOGY: Adenocarcinoma consistent with high-grade serous carcinoma\nPLATINUM: status=Unknown; pfi_days=Unknown\nBIOMARKERS: CA125=Unknown; AFP=Unknown; TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2201222; date=2022-01-24; full_text=HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:22.355452&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;HRDâ€‘positive, BRCA1/2â€‘negative highâ€‘grade serous ovarian carcinoma, postâ€“primary debulking and firstâ€‘line platinum chemotherapy (platinumâ€‘sensitive), with prior extensive peritoneal and nodal metastases; history of severe niraparibâ€‘induced thrombocytopenia but organ function otherwise acceptable; histology: High-grade serous carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:22.355461&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:30.556152&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:32.945671&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
